Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed is viewed favorably because its AI-enabled aprevo platform is differentiated by personalized implants, strong clinical data, and favorable reimbursement that can drive surgeon adoption and higher facility economics. Revenue momentum appears durable, with FY26 guidance reaffirmed at roughly $74 million to $78 million, active surgeons at 284 as of 1Q26, and gross margin expected in the mid- to high-70%s, while new launches such as cervical, corra, and the bilateral posterior fusion system could extend growth. The capital-light model, lower commission structure, 165+ issued or pending patents, and management’s belief that cash flow breakeven is achievable on less than $200 million of revenue support a credible path toward profitability.

Carlsmed is facing a fundamentally challenged setup because its growth depends on rapid adoption of aprevo, yet the bear case assumes revenue growth slows to 10-20% over the modeling horizon and profitability arrives later than expected. The competitive backdrop is especially harsh, with the top five public incumbents controlling about 75% of the global spine market, while Globus Medical’s SCRIPT launch and broader next-generation implant development could pressure share gains, pricing, and surgeon adoption. It is also currently unprofitable, with consensus modeling adjusted EBITDA of ($33M), ($27M), and ($12M) for 2026, 2027, and 2028, so any reimbursement changes, slower hospital approvals, or higher operating expense spend could trigger multiple contraction.